PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
61.25 USD
+1.31 (+2.19%)
Overall PBH gets a fundamental rating of 6 out of 10. We evaluated PBH against 191 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
In the past year PBH had a positive cash flow from operations.
PBH had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
PBH has a Return On Assets of 5.83%. This is amongst the best in the industry. PBH outperforms 86.91% of its industry peers.
PBH has a Return On Equity of 11.00%. This is amongst the best in the industry. PBH outperforms 85.86% of its industry peers.
Looking at the Return On Invested Capital, with a value of 7.88%, PBH belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
With an excellent Profit Margin value of 18.09%, PBH belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
PBH's Profit Margin has improved in the last couple of years.
PBH's Operating Margin of 31.00% is amongst the best of the industry. PBH outperforms 94.24% of its industry peers.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
The Gross Margin of PBH (56.10%) is better than 68.06% of its industry peers.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PBH has been reduced compared to 1 year ago.
Compared to 5 years ago, PBH has less shares outstanding
The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
PBH has an Altman-Z score of 2.52. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.52, PBH is in the better half of the industry, outperforming 63.87% of the companies in the same industry.
PBH has a debt to FCF ratio of 3.97. This is a good value and a sign of high solvency as PBH would need 3.97 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.97, PBH belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
The Debt to Equity ratio of PBH (0.55) is worse than 65.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.52 |
ROIC/WACC0.91
WACC8.66%
2.3 Liquidity
A Current Ratio of 3.70 indicates that PBH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.70, PBH is in line with its industry, outperforming 57.07% of the companies in the same industry.
A Quick Ratio of 2.51 indicates that PBH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.51, PBH is in line with its industry, outperforming 50.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.15%, which is quite good.
Measured over the past years, PBH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.88% on average per year.
PBH shows a decrease in Revenue. In the last year, the revenue decreased by -0.02%.
PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
The Earnings Per Share is expected to grow by 4.13% on average over the next years.
Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.15% on average per year.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.43, the valuation of PBH can be described as correct.
87.43% of the companies in the same industry are more expensive than PBH, based on the Price/Earnings ratio.
PBH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.29.
Based on the Price/Forward Earnings ratio of 12.51, the valuation of PBH can be described as correct.
84.29% of the companies in the same industry are more expensive than PBH, based on the Price/Forward Earnings ratio.
PBH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.51.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.43 | ||
| Fwd PE | 12.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaply inside the industry as 86.91% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PBH is valued cheaper than 88.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.53 | ||
| EV/EBITDA | 10.11 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)8.19
PEG (5Y)1.51
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:PBH (12/10/2025, 11:53:04 AM)
61.25
+1.31 (+2.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners108.93%
Inst Owner Change-0.57%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap2.94B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (29.06%)
Short Float %3.32%
Short Ratio3.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)-4.08%
PT rev (3m)-7.3%
EPS NQ rev (1m)-8.06%
EPS NQ rev (3m)-9.11%
EPS NY rev (1m)0.96%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)-2.41%
Revenue NQ rev (3m)-5.22%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.43 | ||
| Fwd PE | 12.51 | ||
| P/S | 2.65 | ||
| P/FCF | 11.53 | ||
| P/OCF | 11.18 | ||
| P/B | 1.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.11 |
EPS(TTM)4.56
EY7.44%
EPS(NY)4.9
Fwd EY7.99%
FCF(TTM)5.31
FCFY8.67%
OCF(TTM)5.48
OCFY8.95%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)8.19
PEG (5Y)1.51
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.52 |
F-Score7
WACC8.66%
ROIC/WACC0.91
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.